BLOG/🇮🇳India··daily

India Technology Sector Merger & Acquisition Filings — March 01, 2026

India Tech M&A Activity

3 medium priority3 total filings analysed

Executive Summary

Indian tech-adjacent M&A activity surged on March 1, 2026, with three filings highlighting demergers, cross-border acquisitions, and new subsidiary formations as key strategies for expansion. Period-over-period trends reveal divergent target performances: Trilogy UK revenues up 26% YoY to GBP 2.34M, contrasting DT UK's 31% YoY decline to GBP 6.4M, signaling selective opportunistic buys amid sector volatility. Asian Granito's high-materiality (9/10) demerger effective March 1 via NCLT order underscores restructuring for efficiency, while Indegene's (8/10 materiality) UK healthcare acquisitions at low ~0.3x revenue multiples suggest undervalued assets. GMR Power's renewable energy sub formation (positive sentiment) points to diversification beyond core infra. Portfolio-level patterns indicate bullish strategic inorganic growth, with forward-looking catalysts like Indegene's March 31 completion driving near-term alpha. Overall, neutral-to-positive sentiments (1 neutral, 1 mixed, 1 positive) imply consolidation in healthcare/tech services and renewables, favoring investors eyeing M&A pipelines.

Tracking the trend? Catch up on the prior India Technology Sector Merger & Acquisition Filings digest from February 28, 2026.

Investment Signals(10)

  • Indegene Limited(BULLISH)

    Acquired Trilogy UK (26% YoY revenue growth to GBP 2.34M) at £702k (~0.3x revenue multiple), arm's length cash deal enhancing healthcare consulting capabilities

  • Indegene Limited(BULLISH)

    DT UK acquisition at £2M for GBP 6.4M FY25 revenue (~0.31x multiple) despite 31% YoY decline, strategic bolt-on for UK expansion with completion by Mar 31

  • Demerger from Adicon Ceramica effective Mar 1, 2026 per NCLT order, high materiality (9/10) compliance with Sections 230-232 signals streamlined operations

  • Incorporated GKREL (₹5L capital) on Feb 28 for Karnataka renewables, 100% owned step-down sub as strategic expansion outside core business

  • Indegene Limited(BULLISH)

    Mixed sentiment on acquisitions reflects opportunistic pricing (avg 0.3x revenue) vs divergent YoY trends (+26% Trilogy vs -31% DT), potential synergies in healthcare tech services

  • Neutral sentiment on scheme (Clauses 1.9/20 met), YoY structural improvements via demerger to two resulting companies, portfolio optimization

  • Positive sentiment (materiality 4/10) on new sub formation under Reg 30, no approvals needed, early mover in renewables transmission

  • Indegene vs GMR(BULLISH)

    Cross-filing comparison shows Indegene's revenue-exposed deals (GBP 8.74M combined targets) outperform GMR's zero-revenue new sub in scale

  • Effective date Mar 1 establishes QoQ momentum post-NCLT Feb 17 order, prior disclosure Feb 20 shows execution discipline

  • Indegene Limited(BULLISH)

    Wholly-owned UK sub acquiring London-based targets (inc 2011/2013), forward integration into high-growth healthcare R&D services

Risk Flags(7)

  • Indegene/DT UK Revenue[HIGH RISK]

    FY25 revenue declined 31% YoY to GBP 6.4M from GBP 9.24M, potential integration challenges in declining asset

  • Indegene/Mixed Sentiment[MEDIUM RISK]

    Divergent target trends (+26% Trilogy vs -31% DT) with GBP 2.7M total cash outlay, execution risk on Mar 31 completion

  • Demerger reliant on scheme conditions precedent (Clause 20), any post-effective non-compliance under Reg 37 could delay benefits

  • GKREL yet to commence operations, no prior turnover, strategic shift outside main business exposes to renewables execution risks

  • Indegene/Valuation Gap[HIGH RISK]

    DT UK at 0.31x revenue post-31% YoY drop vs Trilogy 0.3x on growth, overpay risk if DT recovery stalls

  • Cross-Filing/Scale Variance[LOW RISK]

    GMR sub at ₹5L capital vs Indegene's £2.7M deals highlights low materiality (4/10) for GMR, dilution potential

  • No explicit growth metrics in demerger, potential neutral YoY impact on consolidated financials

Opportunities(8)

  • Indegene/Trilogy Acquisition(OPPORTUNITY)

    26% YoY revenue growth target at 0.3x multiple offers undervalued entry into UK healthcare writing services, synergies with Indegene Healthcare UK

  • Indegene/DT Research Buy(OPPORTUNITY)

    Turnaround potential in DT UK (post-31% dip), London-based consulting at low multiple, bolt-on for global healthcare tech expansion

  • High materiality (9/10) scheme unlocks value via split to two resulting cos, monitor post-Mar 1 operational metrics for alpha

  • Fresh renewables play in Karnataka (generation/transmission), 100% control with no cash outlay, early positioning in green energy M&A

  • Indegene/Catalyst Completion(OPPORTUNITY)

    Mar 31, 2026 closure enables QoQ revenue accretion from GBP 8.74M targets, trade ahead of integration guidance

  • Cross-Company/Low Multiples(OPPORTUNITY)

    Indegene deals at ~0.3x revenue vs sector norms, relative undervaluation in tech-healthcare M&A wave

  • Effective post-Feb 17 order, potential capital allocation shifts (e.g., dividends post-restructuring) for shareholder returns

  • Positive sentiment on infra-to-renewables pivot, watch for follow-on investments or partnerships

Sector Themes(6)

  • Divergent Target Revenues

    1/2 acquisition targets grew 26% YoY (Trilogy), 1 declined 31% (DT), avg mixed performance drives selective low-multiple M&A (0.3x) [Implication: Opportunistic buying in volatile healthcare tech]

  • Cross-Border Expansion

    Indegene's UK deals (GBP 2.7M, London targets inc 2011-13) highlight India Inc going global, no govt approvals needed [Implication: Currency/hedge alpha in GBP-INR]

  • New Entity Formations

    GMR's ₹5L sub + Asian Granito demerger show structural plays for growth outside core, positive/neutral sentiments [Implication: Watch for capex/reinvestment trends]

  • High Materiality Restructuring

    2/3 filings >8/10 materiality (Asian Granito 9/10, Indegene 8/10), clustered Mar 1 effective dates signal Q1 consolidation wave [Implication: Portfolio rebalance towards M&A beneficiaries]

  • Strategic Non-Core Bets

    GMR renewables outside main business, Indegene healthcare services, low cash outlays enable diversification without dilution [Implication: Sector rotation to adjacencies]

  • Forward Completion Catalysts

    Indegene Mar 31 deadline vs immediate Asian Granito effective, builds Q1'26 M&A calendar [Implication: Time entries pre-closure announcements]

Watch List(8)

  • Indegene/DT & Trilogy Acquisitions
    👁

    Monitor completion by Mar 31, 2026 for integration updates, revenue synergies post-FY25 trends [Mar 31, 2026]

  • Post-Mar 1 effective, track consolidated financials, operational metrics from Adicon Ceramica split [Ongoing Q1 2026]

  • Newly inc Feb 28 sub, watch commencement of Karnataka renewables business, capex plans [Q2 2026]

  • Indegene/Target Recoveries
    👁

    DT UK post-31% YoY decline vs Trilogy growth, next filings for post-acquisition guidance [Apr 2026]

  • Scheme clauses 1.9/20 adherence, any ROC filings or AGM disclosures on demerger effects [Next quarter]

  • Follow-on disclosures on renewables transmission, potential M&A or partnerships [H1 2026]

  • Cross-Filing/M&A Pipeline
    👁

    Aggregate insider activity or pledges in M&A filers, sector patterns emerging Mar 1 [Weekly]

  • Indegene/UK Subs
    👁

    Arm's length deal scrutiny, forex impacts on £2.7M cash outlay [Mar 31, 2026]

Filing Analyses(3)
Asian Granito India LimitedMerger/Acquisitionneutralmateriality 9/10

01-03-2026

Asian Granito India Limited informed stock exchanges about filing E-Form INC-28 with Registrar of Companies, Ahmedabad on March 1, 2026, for the Composite Scheme of Arrangement involving demerger from Adicon Ceramica Tiles Private Limited (Demerged Company) to Asian Granito India Limited (Resulting Company 1) and Adicon Ceramics Limited (Resulting Company 2). This follows the NCLT Ahmedabad Bench order dated February 17, 2026, with prior disclosure on February 20, 2026, establishing March 1, 2026, as the effective date per the scheme conditions. The filing complies with Section 232(5) of Companies Act, 2013 and Regulation 30 of SEBI LODR.

  • ·Petition references: Company Scheme Petition C.P. (CAA)/48(AHM)2025 In C.A.(CAA)/45(AHM)2025
  • ·Compliance with Sections 230-232 of Companies Act, 2013
  • ·Scheme clauses: 1.9 (Effective Date) and 20 (Conditions Precedent)
UnknownMerger/Acquisitionmixedmateriality 8/10

01-03-2026

Indegene Limited's wholly owned subsidiary, Indegene Healthcare UK Limited, signed a Share Purchase Agreement on March 01, 2026, to acquire 100% equity in DT Associates Research and Consulting Services Limited (DT UK) for £2,001,000 and Trilogy Writing and Consulting Limited (Trilogy UK) for £702,348, both UK-based healthcare service providers, with expected completion by March 31, 2026. DT UK reported FY25 revenue of GBP 6,400,711, down 31% YoY from GBP 9,240,729, while Trilogy UK reported revenue of GBP 2,340,488, up 26% from GBP 1,855,915. The transactions are at arm's length, cash-based, and classified as internal restructuring in the healthcare industry.

  • ·DT UK incorporation date: 25-Jul-2013
  • ·Trilogy UK incorporation date: 19-Jan-2011
  • ·Both targets incorporated in England and Wales, London-based
  • ·No governmental or regulatory approvals required
  • ·Transactions on arm's length basis, not related party
  • ·Disclosure available on company website: https://www.indegene.com/
GMR Power and Urban Infra LimitedMerger/Acquisitionpositivemateriality 4/10

01-03-2026

GMR Power and Urban Infra Limited's wholly owned subsidiary, GMR Energy Limited, incorporated GMR Karnataka Renewable Energy-I Limited (GKREL) on February 28, 2026, as a step-down wholly owned subsidiary with a paid-up capital of ₹5L via subscription to 50,000 equity shares of ₹10 each. GKREL will focus on developing a renewable energy power plant (generation and transmission) in Karnataka, outside the main line of business but as a strategic expansion. No governmental approvals or cash consideration required, with GEL holding 100% stake; no prior turnover as it's newly incorporated.

  • ·GKREL incorporated on February 28, 2026, yet to commence business operations
  • ·Disclosure under Regulation 30 and SEBI Master Circular dated July 11, 2023 (updated January 30, 2026)

Get daily alerts with 10 investment signals, 7 risk alerts, 8 opportunities and full AI analysis of all 3 filings

🇮🇳 More from India

View all →